1. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, ran...
phase III trial of pertuzumab re-treatment in HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab, and chemotherapy: the Japan Breast Cancer Research Group-M05 (PRECIOUS) study. Cancer Res 2021;81(4 suppl). ...
phase III trial of pertuzumab re-treatment in HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab, and chemotherapy: the Japan Breast Cancer Research Group-M05 (PRECIOUS...
近年来,多项回顾性研究已经探讨了HER2低表达在早期乳腺癌中的预后意义,但并未达成一致结论。近日,《Cancer Treatment Reviews》(IF:13.608)发表了一项Meta分析,评估了HER2 0和HER2低表达在早期乳腺癌患者的临床病理特征和生存预后方面是否存在差异[1]。该项Mata共纳入23项回顾性研究,包括636,535例患者。结果显示,在H...
Escriva-de-Romaní ´ SI, et al. Primary outcome of the phase III SYD985.002/TULIP trial comparing [vic-]trastuzumab duocarmazine to physician’s choice treatment in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer. Ann Oncol 2021;32(suppl 5):S1288. Abstr...
19、Shanu Modi,et al.Trastuzumab deruxtecan(T-DXd)vs treatment of physician’s choice(TPC)in patients(pts)with HER2-low,hormone receptor-positive(HR+)unresectable and/or metastatic breastcancer(mBC):Exploratory biomarker analysis of DESTINY-Breast04.2023 ASCO Abstract1020. ...
在发现了neu之后,Weinberg教授并没有太在意它,当时,他的团队在努力攻坚RAS基因的克隆。这给了其他人一个机会,没过两年,就有几个不同团队的研究人员成功克隆出了HER2,测出了完整的序列,并确定了它位于17号染色体上[3,4,5]。 1987年,这也是乳腺癌治疗史上里程碑式的一年,加州大学洛杉矶分校的Dennis Slamon博士联...
6.Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010 Aug 28;376(9742...
HER-Vaxx是一种B细胞免疫治疗,用于治疗HER2/neu受体过表达的肿瘤,包括胃癌。结果显示,与单独化疗相比,HER-Vaxx 联合化疗的中位OS显著更长(14.0 vs 8.3个月),HER-Vaxx 联合化疗的中位缓解持续时间更长(30 vs 19周),两组的安全性相似,HER-Vaxx联合化疗未见额外的毒性。目前正在单臂2期扩展研究中探索HER-Va...
[6]Lara PN Jr, Laptalo L, Longmate J, et al. Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: a California Cancer Consortium screening and phase II trial. Clin Lung Cancer. 2004 Jan;5(...